scholarly journals Chemical composition and antimicrobial activity of leave extract of Ocimum lamiifolium (Damakese) as a treatment for urinary tract infection

2018 ◽  
Vol 4 (1) ◽  
pp. 1440894 ◽  
Author(s):  
Nigus Aweke Sahalie ◽  
Lijalem Hadush Abrha ◽  
Leta Deressa Tolesa ◽  
Oleg Rakitin
Keyword(s):  
Antimicrobial Activity ◽  
Urinary Tract Infection ◽  
Urinary Tract ◽  
Chemical Composition ◽  
Tract Infection

scholarly journals Antimicrobial Activity of Intraurethrally Administered Probiotic Lactobacillus casei in a Murine Model of Escherichia coli Urinary Tract Infection

2001 ◽  
Vol 45 (6) ◽  
pp. 1751-1760 ◽  
Author(s):  
Takashi Asahara ◽  
Koji Nomoto ◽  
Masaaki Watanuki ◽  
Teruo Yokokura
Keyword(s):  
Escherichia Coli ◽  
Antimicrobial Activity ◽  
Urinary Tract Infection ◽  
Urinary Tract ◽  
Tract Infection ◽  
Lactobacillus Casei ◽  
Inflammatory Responses ◽  
Challenge Infection ◽  
Myeloperoxidase Activity ◽  
Infection Period

ABSTRACT The antimicrobial activity of the intraurethrally administered probiotic Lactobacillus casei strain Shirota againstEscherichia coli in a murine urinary tract infection (UTI) model was examined. UTI was induced by intraurethral administration ofEscherichia coli strain HU-1 (a clinical isolate from a UTI patient, positive for type 1 and P fimbriae), at a dose of 1 × 106 to 2 × 106 CFU in 20 μl of saline, into a C3H/HeN mouse bladder which had been traumatized with 0.1 N HCl followed immediately by neutralization with 0.1 N NaOH 24 h before the challenge infection. Chronic infection with the pathogen at 106 CFU in the urinary tract (bladder and kidneys) was maintained for more than 3 weeks after the challenge, and the number of polymorphonuclear leukocytes and myeloperoxidase activity in the urine were markedly elevated during the infection period. A single administration of L. casei Shirota at a dose of 108 CFU 24 h before the challenge infection dramatically inhibited E. coli growth and inflammatory responses in the urinary tract. Multiple daily treatments with L. casei Shirota during the postinfection period also showed antimicrobial activity in this UTI model. A heat-killed preparation ofL. casei Shirota exerted significant antimicrobial effects not only with a single pretreatment (100 μg/mouse) but also with multiple daily treatments during the postinfection period. The otherLactobacillus strains tested, i.e., L. fermentum ATCC 14931T, L. jensenii ATCC 25258T, L. plantarum ATCC 14917T, and L. reuteri JCM 1112T, had no significant antimicrobial activity. Taken together, these results suggest that the probiotic L. casei strain Shirota is a potent therapeutic agent for UTI.

scholarly journals Antimicrobial Efficacy of Chromolaena odorata Extract against Bacteria Isolated from Patients with Urinary Tract Infection in Ondo State, Nigeria

2018 ◽  
pp. 1-10
Author(s):  
Anthony Okhonlaye Ojokoh ◽  
Olumide Mogaji ◽  
Bartholomew Saanu Adeleke
Keyword(s):  
Antimicrobial Activity ◽  
Urinary Tract Infection ◽  
Urinary Tract ◽  
Tract Infection ◽  
Urine Samples ◽  
Antimicrobial Efficacy ◽  
Chromolaena Odorata ◽  
Candida Sp ◽  
Ondo State ◽  
Tract Infections

Aim: This study is designed to isolate and identify the microorganisms associated with urinary tract infection in infected patients, determine the antimicrobial resistance pattern on the microbial isolates and the antimicrobial efficacy of solvents leaf extract of Chromolaena odorata on the resistant isolates. Methodology: Six hundred (600) mid-stream urine samples were collected from infected patients in some selected hospitals in Ondo State. The phytochemical screening of the plant was determined. The antibiotics sensitivity and antimicrobial activity of the plant extract was determined using plate assay and agar well diffusion methods. Results: Out of 600 urine samples analyzed, 472 (78.68%) showed significant growth of uropathogens comprising 197 (32.80%) male and 275 (45.83%) female. The isolated microorganisms comprise 5 Gram-positive bacteria (GPB), 9 Gram-negative bacteria (GNB) and 4 Candida sp. GNB account for 284(58.79%), GPB 158(32.71%) and Candida sp 41(8.48%). Escherichia coli showed high prevalence 90(18.63%) while Klebsiella ozaenae showed the least 11(2.27%). The phytochemical constituents of C. odorata extracts contained tannins, flavonoids, saponins, steroids and terpernoids and bacterial isolates showed resistant to all the antibiotics. Pseudomonas mendocina and P. putida showed the least resistant to C. odorata extracts. The MIC of the leaf extracts ranged from 5.0 mg/ml to 50.0 mg/ml.  The methanol extract had the highest antimicrobial activity than n-hexane and chloroform extracts on the uropathogens. Conclusion: The high therapeutic potentials of C. odorata extract against the uropathogens could be used as alternative phytotherapy in herbal medicine to the commercial antibiotics in the treatment of urinary tract infections.

scholarly journals Antimicrobial Activity Evaluation of Tebipenem (SPR859), an Orally Available Carbapenem, against a Global Set of Enterobacteriaceae Isolates, Including a Challenge Set of Organisms

2019 ◽  
Vol 63 (6) ◽  
Author(s):  
S. J. Ryan Arends ◽  
Paul R. Rhomberg ◽  
Nicole Cotroneo ◽  
Aileen Rubio ◽  
Robert K. Flamm ◽  
...  
Keyword(s):  
Escherichia Coli ◽  
Antimicrobial Activity ◽  
Urinary Tract Infection ◽  
Urinary Tract ◽  
Tract Infection ◽  
Broth Microdilution ◽  
Wild Type ◽  
Content Type ◽  
E Coli

ABSTRACT The antimicrobial activity of tebipenem and other carbapenem agents were tested in vitro against a set of recent clinical isolates responsible for urinary tract infection (UTI), as well as against a challenge set. Isolates were tested by reference broth microdilution and included Escherichia coli (101 isolates), Klebsiella pneumoniae (208 isolates), and Proteus mirabilis (103 isolates) species. Within each species tested, tebipenem showed equivalent MIC50/90 values to those of meropenem (E. coli MIC50/90, ≤0.015/0.03 mg/liter; K. pneumoniae MIC50/90, 0.03/0.06 mg/liter; and P. mirabilis MIC50/90, 0.06/0.12 mg/liter) and consistently displayed MIC90 values 8-fold lower than imipenem. Tebipenem and meropenem (MIC50, 0.03 mg/liter) showed equivalent MIC50 results against wild-type, AmpC-, and/or extended-spectrum β-lactamase (ESBL)-producing isolates. Tebipenem also displayed MIC50/90 values 4- to 8-fold lower than imipenem against the challenge set. All carbapenem agents were less active (MIC50, ≥8 mg/liter) against isolates carrying carbapenemase genes. These data confirm the in vitro activity of the orally available agent tebipenem against prevalent UTI Enterobacteriaceae species, including those producing ESBLs and/or plasmid AmpC enzymes.

Sign in / Sign up

Export Citation Format

Share Document